Several clinical trials of evogliptin administration among healthy subjects without diabetes showed good tolerability within the dose range of 1.25–60 mg and dose-dependent DPP-4 inhibition: no subjects developed hypoglycemia [41,42]. Here, DPP4 is linked to Hypoglycemia.